Weight loss medications: GLP-1 market shift 2026

US searchers logged 165,000 monthly queries for weight loss medications in the June 2026 NovaPharmaNews Search Demand Index. This analysis pairs that proprietary demand signal with FDA labels and SEC-filed revenue for Wegovy and Zepbound—not syndicated market-share totals we cannot verify against primary sources.

Key Takeaways

FDA approved Wegovy (semaglutide, NDA 215256) for chronic weight management in June 2021 and Zepbound (tirzepatide) on November 8, 2023.
Novo Nordisk Q1 2026 adjusted Total Obesity care sales were DKK 20,912 million (+22% at CER), with Wegovy injectable at DKK 18,235 million and Wegovy pill at DKK 2,256 million.
Eli Lilly reported full-year 2025 Zepbound revenue of $13.542 billion (+175% vs 2024) and Q4 2025 Zepbound sales of $4.261 billion.
Registry anchors include OASIS 4 (NCT05564174) and SURMOUNT-5 (NCT05822830); Part D/MA coverage claims wait on verified CMS primaries.

What do FDA labels say about leading weight loss medications?

Two FDA-approved injectables define the current US regulatory floor for chronic weight management. Wegovy (semaglutide) was approved under NDA 215256 in June 2021 as an adjunct to diet and activity for adults with obesity or overweight plus at least one weight-related comorbidity.

The current FDA Wegovy prescribing information also covers cardiovascular-risk reduction in adults with established CV disease and obesity or overweight, pediatric obesity from age 12, and accelerated approval for noncirrhotic MASH with F2–F3 fibrosis.

On November 8, 2023, the FDA approved Zepbound (tirzepatide) for chronic weight management in adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² plus a weight-related condition, per the agency’s Zepbound approval announcement. Label dosing titrates over weeks to 5 mg, 10 mg, or 15 mg once weekly.

How large is verified demand for weight loss medications?

The NovaPharmaNews Search Demand Index (US snapshot dated 2026-06-17) shows 165,000 monthly organic searches for the head term “weight loss medications.” That figure is proprietary search intelligence, not prescriptions, claims, or retail units.

Intent on the head term is informational and class-level. We do not treat search volume as a substitute for payer enrollment or filled scripts. The signal is useful because it tracks access-oriented demand sitting above any single brand query cluster.

Query	US monthly volume	Intent	Competition
weight loss medications	165,000	informational	1.00

What did Novo Nordisk disclose for obesity care in Q1 2026?

Novo Nordisk’s Q1 2026 interim report, filed with the SEC, is the filing-grade source for obesity revenue in this piece. Adjusted Total Obesity care sales reached DKK 20,912 million, up 22% at constant exchange rates.

Brand-level adjusted sales in the same filing show Wegovy injectable at DKK 18,235 million (+12% at CER) and Wegovy pill at DKK 2,256 million after a January 5, 2026 US launch. US Operations obesity care grew 9% at CER; International Operations grew 44% at CER.

We cite the Novo Nordisk Q1 2026 SEC interim report verbatim and exclude third-party market-share percentages that do not appear in that filing.

What did Eli Lilly report for Zepbound in 2025?

Eli Lilly’s Q4 2025 sales and earnings release, also on SEC EDGAR, reports full-year 2025 Zepbound revenue of $13.542 billion, up 175% from $4.926 billion in 2024. Q4 2025 Zepbound sales were $4.261 billion, up 123% year over year.

US Zepbound revenue in Q4 2025 rose 122% to about $4.2 billion on higher demand, partially offset by lower realized prices. Company-level 2026 revenue guidance in the same release is $80–$83 billion—guidance, not a product-level obesity forecast.

Primary source: Eli Lilly Q4 2025 SEC sales and earnings release.

Which trials and payer documents still matter?

Two ClinicalTrials.gov records remain useful registry anchors for oral and comparative obesity programs:

Novo Nordisk oral semaglutide obesity program OASIS 4 — NCT05564174
Eli Lilly tirzepatide comparative obesity program SURMOUNT-5 — NCT05822830

CMS Part D prescription drug coverage materials frame the payer policy context. We date Medicare Advantage GLP-1 coverage catalysts only after a live CMS primary confirms the claim.

What remains unproven in the 2026 market narrative?

Filing-backed revenue and FDA labels do not establish prescription market share, naïve-patient mix, or syndicated “global obesity market” totals. Those figures are omitted until a primary filing or regulator page supports them.

Gross-to-net dynamics, capacity constraints, and Part D formulary status can move faster than quarterly sales lines. Until CMS or plan documents are verified, we treat access narratives as open questions rather than dated catalysts.

Entity pages for semaglutide, tirzepatide, Novo Nordisk, and Eli Lilly carry the molecule- and sponsor-level context that this market overview does not duplicate.

Related NovaPharma coverage

Frequently Asked Questions

What verified obesity revenue did Novo Nordisk report for Q1 2026?

Novo Nordisk reported adjusted Total Obesity care sales of DKK 20,912 million in Q1 2026, up 22% at constant exchange rates, including Wegovy injectable sales of DKK 18,235 million and Wegovy pill sales of DKK 2,256 million, per its SEC-filed interim report.

How large was Zepbound revenue in Eli Lilly’s 2025 filing?

Eli Lilly reported full-year 2025 Zepbound revenue of $13.542 billion, up 175% from $4.926 billion in 2024, with Q4 2025 Zepbound sales of $4.261 billion, according to its Q4 2025 sales and earnings release filed with the SEC.

Which FDA-approved weight loss medications anchor this analysis?

This analysis centers on Wegovy (semaglutide) and Zepbound (tirzepatide). The FDA approved Wegovy for chronic weight management in June 2021 (NDA 215256) and approved Zepbound for chronic weight management on November 8, 2023.